🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Evolus Inc (EOLS)

NASDAQ
Currency in USD
16.75
+0.43(+2.63%)
Closed
After Hours
16.86+0.11(+0.66%)
EOLS Scorecard
Full Analysis
Analysts do not anticipate the company will be profitable this year
Fair Value
Day's Range
16.3516.77
52 wk Range
7.7417.82
Prev. Close
16.32
Open
16.41
Day's Range
16.35-16.77
52 wk Range
7.74-17.82
Volume
374,409
Average Volume (3m)
569,931
1-Year Change
115.3%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
EOLS Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
23.43
Upside
+39.88%
Members' Sentiments
Bearish
Bullish
ProTips
High return over the last year
Show more

InvestingPro Research for Evolus Inc


Aesthetic Innovato
Evolus Inc. positions itself as a key player in medical aesthetics, focusing on toxins and fillers, with ambitious revenue targets and a growing market presence.
Financial Trajectory
Discover Evolus' path to profitability, with Q4 2024 projections and analyst expectations of EPS improvement from -0.22 in FY1 to 0.04 in FY2.
Product Pipeline
Explore Evolus' growth strategy, centered on Jeuveau's performance and the potential launch of Evolysse Fillers, set to expand the company's market reach.
Market Dynamics
Delve into the competitive landscape of medical aesthetics, where Evolus faces established players while leveraging educational initiatives to gain market share.
Read full SWOT analysis

Evolus Company Profile

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Employees
279

Compare EOLS to Peers and Sector

Metrics to compare
EOLS
Peers
Sector
Relationship
P/E Ratio
−19.9x−1.9x−0.6x
PEG Ratio
−0.850.010.00
Price/Book
54.7x0.7x2.6x
Price / LTM Sales
4.5x1.3x3.2x
Upside (Analyst Target)
49.3%72.1%48.9%
Fair Value Upside
Unlock27.0%7.2%Unlock

FAQ

What Is the Evolus (EOLS) Stock Price Today?

The Evolus stock price today is 16.75.

What Stock Exchange Does Evolus Trade On?

Evolus is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Evolus?

The stock symbol for Evolus is "EOLS."

What Is the Evolus Market Cap?

As of today, Evolus market cap is 1.06B.

What is Evolus Earnings Per Share?

The Evolus EPS is -0.903.

What Is the Next Evolus Earnings Date?

Evolus will release its next earnings report on 25 Feb 2025.

From a Technical Analysis Perspective, Is EOLS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.